Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices - 2Find the Captivating Professional flowerbeds of the US
- 3Moon milestones: A rundown of Artemis 2's many spaceflight firsts
- 4Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- 5NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- The Best Competitors of the 21st Hundred years
- Instructions to Pick the Best Album Rates for Your Investment funds
- Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis
- 2 ways you can conserve the water used to make your food
- Ancient meditation practices find new life in modern religious communities across America
- 6 Eyewear Brands Worth Purchasing
